Vaccination against SARS-COV-2: side effects of the CHADOX1NCOV-19 vaccine (AstraZeneca)
DOI:
https://doi.org/10.51798/sijis.v3i3.402Keywords:
COVID-19; side effects; ChAdOx1 nCoV-19; clinical trials; vector AdenovirusAbstract
Covid-19 has impacted the world, altering diferente áreas of development sucha as economical and socials that caused considerable deaths to all social strata. Mass vaccination has been the object of a countermeasure for the pandemic, however, adverse reactions have occurred after vaccination that have concerned the general population. Therefore, it is intended to determine the relationship between side effects and predisposing factors after vaccination against SARS-CoV-2 using ChAdOx1 nCoV-19 (AstraZeneca). A bibliographic review has been carried out following the PRISMA guidelines of the studies found in PubMed and ScienceDirect, including a total of 16 studies. Through them we can asume that risk factors most related to the development of adverse effects to vaccination were women, young people, those under specific pharmacological treatment, with symptoms such as pain in the puncture area and headache standing out, however, the specific relationship between they, have not come to be clear yet due to lack of studies around the main topic.
References
Aladdin, Y., & Shirah, B. (2020). New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine. January.
Ap-, S., & Appendix, S. (n.d.). C or r e sp ondence No Correlation between Anti-PF4 and Anti – SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. 1–3.
Banerji, A., Wickner, P. G., Saff, R., Stone, C. A., Robinson, L. B., Long, A. A., Wolfson, A. R., Williams, P., Khan, D. A., Phillips, E., & Blumenthal, K. G. (2021). mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. Journal of Allergy and Clinical Immunology: In Practice, 9(4), 1423–1437. https://doi.org/10.1016/j.jaip.2020.12.047
Casucci, G., & Acanfora, D. (2021). Dic-like syndrome following administration of chadox1 ncov-19 vaccination. Viruses, 13(6), 1–6. https://doi.org/10.3390/v13061046
Douxfils, J., Favresse, J., Dogn, J., Susen, S., Cordonnier, C., Gosselin, R., & Si, P. (2020). Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. January.
Flaxman, A., Marchevsky, N. G., Jenkin, D., Aboagye, J., Aley, P. K., Angus, B., Belij-Rammerstorfer, S., Bibi, S., Bittaye, M., Cappuccini, F., Cicconi, P., Clutterbuck, E. A., Davies, S., Dejnirattisai, W., Dold, C., Ewer, K. J., Folegatti, P. M., Fowler, J., Hill, A. V. S., … Yao, A. (2021). Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet, 398(10304), 981–990. https://doi.org/10.1016/S0140-6736(21)01699-8
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., … Yau, Y. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396(10249), 467–478. https://doi.org/10.1016/S0140-6736(20)31604-4
Göbel, C. H., Heinze, A., Karstedt, S., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q., Halwani, R., Temsah, M. H., Ziemann, M., Görg, S., Münte, T., & Göbel, H. (2021). Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and Therapy, 10(2), 1309–1330. https://doi.org/10.1007/s40122-021-00296-3
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 384(22), 2092–2101. https://doi.org/10.1056/nejmoa2104840
Haimei, M. A. (2021). Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination. Clinical and Applied Thrombosis/Hemostasis, 27. https://doi.org/10.1177/10760296211040110
Jęśkowiak, I., Wiatrak, B., Grosman-Dziewiszek, P., & Szeląg, A. (2021). The incidence and severity of post-vaccination reactions after vaccination against covid-19. Vaccines, 9(5). https://doi.org/10.3390/vaccines9050502
K. Allen-Philbeya, b, A. Stennetta, b, T. Begumb, AC. Johnsonb, R. Dobsonb, c, G. Giovannonia, b, c, S. Gnanapavana, b, M. Martaa, b, I. Smetsa, b, B.P. Turnera, b, D. Bakera, J. Mathewsd, K. S. (2020). Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. January, 4.
Kim, J. H., Marks, F., & Clemens, J. D. (2021). Looking beyond COVID-19 vaccine phase 3 trials. Nature Medicine, 27(2), 205–211. https://doi.org/10.1038/s41591-021-01230-y
Kircheis, R. (2021). Coagulopathies after vaccination against sars-cov-2 may be derived from a combined effect of sars-cov-2 spike protein and adenovirus vector-triggered signaling pathways. International Journal of Molecular Sciences, 22(19). https://doi.org/10.3390/ijms221910791
Lee, S. W., Moon, J., Lee, S., Lee, H., & Moon, S. (2021). Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 ( AZD1222 ) Vaccine in Healthcare Workers : Lack of Association With Age , Sex , Obesity , and Adverse Reactions Characteristics of the Subjects. 12(November), 1–8. https://doi.org/10.3389/fimmu.2021.779212
Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., Dinesh, T., England, A., Faust, S. N., Ferreira, D. M., Finn, A., Green, C. A., Hallis, B., Heath, P. T., Hill, H., … Allen, L. (2021). Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet, 398(10303), 856–869. https://doi.org/10.1016/S0140-6736(21)01694-9
Mahase, E. (2021). Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. The BMJ, 372(March), 19–20. https://doi.org/10.1136/bmj.n774
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3
Murphy, J., Vallières, F., Bentall, R. P., Shevlin, M., McBride, O., Hartman, T. K., McKay, R., Bennett, K., Mason, L., Gibson-Miller, J., Levita, L., Martinez, A. P., Stocks, T. V. A., Karatzias, T., & Hyland, P. (2021). Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nature Communications, 12(1), 1–15. https://doi.org/10.1038/s41467-020-20226-9
Novak, N., Tordesillas, L., & Cabanillas, B. (2021). Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia. International Reviews of Immunology, December 2020, 1–10. https://doi.org/10.1080/08830185.2021.1939696
Parry, H., Bruton, R., Tut, G., Ali, M., Stephens, C., Greenwood, D., Faustini, S., Hughes, S., Huissoon, A., Meade, R., Brown, K., Amirthalingam, G., Otter, A., Hallis, B., Richter, A., Zuo, J., & Moss, P. (2021). Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy Longevity, 2(9), e554–e560. https://doi.org/10.1016/s2666-7568(21)00169-0
Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021). Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine, 10(7), 1–18. https://doi.org/10.3390/jcm10071428
Riad, A., Pokorná, A., Mekhemar, M., Conrad, J., Klugarová, J., Koščík, M., Klugar, M., & Attia, S. (2021). Safety of chadox1 ncov-19 vaccine: Independent evidence from two eu states. Vaccines, 9(6), 1–12. https://doi.org/10.3390/vaccines9060673
Salma AlBahrani , Ali AlBarraK , Othman Ali Alghamdi , Mesfer Abdullah alghamdi , Fatimah H. Hakami , Asmaa K. Al Abaadi , Sausan A. Alkhrashi , Mansour Y. Alghamdi , Meshael M. Almershad , Mansour Moklif Alenazi , Mohamed Hany ElGezery , Arulanantham Zec, J. A. A.-T. (2020). Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Vaccinee in Saudi Arabia. January.
Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Schneitler, S., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M. (2021). Immunogenicity and reactogenicity of vaccination. Nature Medicine, 27(September). https://doi.org/10.1038/s41591-021-01464-w
Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., & Lester, W. (2021). Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 384(23), 2202–2211. https://doi.org/10.1056/nejmoa2105385
Sørvoll, I. H., Horvei, K. D., Ernstsen, S. L., Lægreid, I. J., Lund, S., Grønli, R. H., Olsen, M. K., Jacobsen, H. K., Eriksson, A., Halstensen, A. M., Tjønnfjord, E., Ghanima, W., & Ahlen, M. T. (2021). An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. Journal of Thrombosis and Haemostasis, 19(7), 1813–1818. https://doi.org/10.1111/jth.15352
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99–111. https://doi.org/10.1016/S0140-6736(20)32661-1
Wise, J. (2021). Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ (Clinical Research Ed.), 372(March), n699. https://doi.org/10.1136/bmj.n699
Yang, J., Ko, J. H., Baek, J. Y., Hong, J., Ha, S., Lee, B., Huh, K., Cho, S. Y., Kang, C. I., Chung, D. R., Kim, Y. J., Kang, E. S., & Peck, K. R. (2021). Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine. Frontiers in Immunology, 12(September), 1–8. https://doi.org/10.3389/fimmu.2021.744206
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Héctor Alexander Leones Sandoval, Carmen Barba Guzmán Variña
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
